ID

14960

Descripción

A Phase II Trial of Lapatinib (TYKERB) + Pemetrexed (ALIMTA) in Advanced Non Small Cell Lung Cancer With an Initial Dose Finding Phase; ODM derived from: https://clinicaltrials.gov/show/NCT00528281

Link

https://clinicaltrials.gov/show/NCT00528281

Palabras clave

  1. 9/5/16 9/5/16 -
Subido en

9 de mayo de 2016

DOI

Para solicitar uno, por favor iniciar sesión.

Licencia

Creative Commons BY 4.0

Comentarios del modelo :

Puede comentar sobre el modelo de datos aquí. A través de las burbujas de diálogo en los grupos de elementos y elementos, puede agregar comentarios específicos.

Comentarios de grupo de elementos para :

Comentarios del elemento para :


Sin comentarios

Para descargar modelos de datos, debe haber iniciado sesión. Por favor iniciar sesión o Registrate gratis.

Eligibility Advanced Non-Small Cell Lung Cancer NCT00528281

Eligibility Advanced Non-Small Cell Lung Cancer NCT00528281

Inclusion Criteria
Descripción

Inclusion Criteria

Alias
UMLS CUI
C1512693
Written informed consent
Descripción

informed consent

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0021430
patients must be 18 years old
Descripción

age

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0001779
subjects must have stage iiib or iv nsclc
Descripción

nsclc

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0007131
recurrent or persistent nsclc following one previous line of cytotoxic chemotherapy
Descripción

cytotoxic chemotherapy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0677881
eastern cooperative oncology group (ecog) performance status (ps) 0-2;
Descripción

ecog

Tipo de datos

boolean

Alias
UMLS CUI [1]
C1520224
life expectancy of 12 weeks
Descripción

life expectancy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0023671
have adequate organ function baseline laboratory values for inclusion
Descripción

organ function

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0678852
Exclusion Criteria
Descripción

Exclusion Criteria

Alias
UMLS CUI
C0680251
history of other malignancy. subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible;
Descripción

malignancy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0455471
known history of or clinical evidence of central nervous system (cns) metastases or leptomeningeal carcinomatosis except for individuals who have previously treated cns metastases, are asymptomatic, and have had no requirement for steroids or antiseizure medication for = 3 months prior to study enrollment.
Descripción

central nervous system metastases

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0686377
peripheral neuropathy of grade 3 or higher
Descripción

peripheral neuropathy

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0031117
concurrent cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, hormonal therapy, and tumor embolization).
Descripción

cconcurrent ancer therapy

Tipo de datos

boolean

Alias
UMLS CUI [1,1]
C0205420
UMLS CUI [1,2]
C0920425
prior exposure to pemetrexed or an egfr inhibitor in combination with 5-fu or a 5fu prodrug.
Descripción

pemetrexed

Tipo de datos

boolean

Alias
UMLS CUI [1]
C0210657

Similar models

Eligibility Advanced Non-Small Cell Lung Cancer NCT00528281

Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de datos
Alias
Item Group
C1512693 (UMLS CUI)
informed consent
Item
Written informed consent
boolean
C0021430 (UMLS CUI [1])
age
Item
patients must be 18 years old
boolean
C0001779 (UMLS CUI [1])
nsclc
Item
subjects must have stage iiib or iv nsclc
boolean
C0007131 (UMLS CUI [1])
cytotoxic chemotherapy
Item
recurrent or persistent nsclc following one previous line of cytotoxic chemotherapy
boolean
C0677881 (UMLS CUI [1])
ecog
Item
eastern cooperative oncology group (ecog) performance status (ps) 0-2;
boolean
C1520224 (UMLS CUI [1])
life expectancy
Item
life expectancy of 12 weeks
boolean
C0023671 (UMLS CUI [1])
organ function
Item
have adequate organ function baseline laboratory values for inclusion
boolean
C0678852 (UMLS CUI [1])
Item Group
C0680251 (UMLS CUI)
malignancy
Item
history of other malignancy. subjects who have been disease-free for 5 years, or subjects with a history of completely resected non-melanoma skin cancer or successfully treated in situ carcinoma are eligible;
boolean
C0455471 (UMLS CUI [1])
central nervous system metastases
Item
known history of or clinical evidence of central nervous system (cns) metastases or leptomeningeal carcinomatosis except for individuals who have previously treated cns metastases, are asymptomatic, and have had no requirement for steroids or antiseizure medication for = 3 months prior to study enrollment.
boolean
C0686377 (UMLS CUI [1])
peripheral neuropathy
Item
peripheral neuropathy of grade 3 or higher
boolean
C0031117 (UMLS CUI [1])
cconcurrent ancer therapy
Item
concurrent cancer therapy (chemotherapy, radiation therapy, surgery, immunotherapy, biologic therapy, hormonal therapy, and tumor embolization).
boolean
C0205420 (UMLS CUI [1,1])
C0920425 (UMLS CUI [1,2])
pemetrexed
Item
prior exposure to pemetrexed or an egfr inhibitor in combination with 5-fu or a 5fu prodrug.
boolean
C0210657 (UMLS CUI [1])

Utilice este formulario para comentarios, preguntas y sugerencias.

Los campos marcados con * son obligatorios.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial